Skip to main content
Premium Trial:

Request an Annual Quote

Tempus to Integrate Genomic Test Ordering Into CureMD's Oncology EHR

NEW YORK – CureMD, maker of technology for community-based oncology practices, said Tuesday that it has formed a partnership with Tempus to integrate genomic test workflows into its electronic health records system.

Initially, CureMD users will be able to order tests from Tempus directly from the EHR. Future integration will support the return of results as discrete data to inform clinical decision-making and risk assessment, according to the New York-based vendor.

"This partnership represents a significant milestone in our commitment to deliver the most cutting-edge solutions to our healthcare providers, ensuring they have the most advanced precision medicine tools at their disposal to provide exceptional patient care," Wasif Toor, CureMD's VP of oncology, said in a statement.

Chicago-based Tempus' menu of oncology tests includes combination solid-tumor and liquid biopsy assays, combination DNA and whole-transcriptome RNA sequencing, tumor-normal testing, and single-platform somatic and germline testing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.